BlackRock’s Ascendis Pharma A/S ASND Stock Holding History

BlackRock’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$590M	Buy	2,211,833 +1,550,779	+235%	+$362M	0.01%	1100
2026 Q1	$151M	Buy	661,054 +32,854	+5%	+$7.36M	﹤0.01%	1844
2025 Q4	$134M	Buy	628,200 +176,703	+39%	+$36.5M	﹤0.01%	1921
2025 Q3	$89.8M	Sell	451,497 -20,229	-4%	-$3.77M	﹤0.01%	2172
2025 Q2	$81.4M	Sell	471,726 -45,428	-9%	-$7.4M	﹤0.01%	2181
2025 Q1	$80.6M	Sell	517,154 -136,134	-21%	-$19.4M	﹤0.01%	2125
2024 Q4	$89.9M	Buy	653,288 +117,184	+22%	+$15.4M	﹤0.01%	2139
2024 Q3	$80M	Buy	536,104 +130,115	+32%	+$17.6M	﹤0.01%	2206
2024 Q2	$55.4M	Buy	405,989 +820	+0.2%	+$112K	﹤0.01%	2350
2024 Q1	$61.2M	Buy	405,169 +56,147	+16%	+$8.01M	﹤0.01%	2323
2023 Q4	$44M	Buy	349,022 +15,456	+5%	+$1.54M	﹤0.01%	2548
2023 Q3	$31.2M	Sell	333,566 -27,524	-8%	-$2.57M	﹤0.01%	2680
2023 Q2	$32.2M	Sell	361,090 -20,009	-5%	-$1.74M	﹤0.01%	2745
2023 Q1	$40.9M	Sell	381,099 -13,671	-3%	-$1.56M	﹤0.01%	2587
2022 Q4	$48.2M	Buy	394,770 +21,146	+6%	+$2.46M	﹤0.01%	2490
2022 Q3	$38.6M	Sell	373,624 -19,536	-5%	-$1.85M	﹤0.01%	2649
2022 Q2	$36.5M	Sell	393,160 -7,924	-2%	-$747K	﹤0.01%	2704
2022 Q1	$47.1M	Buy	401,084 +80,988	+25%	+$9.38M	﹤0.01%	2628
2021 Q4	$43.1M	Sell	320,096 -18,980	-6%	-$2.82M	﹤0.01%	2753
2021 Q3	$54M	Buy	339,076 +3,315	+1%	+$454K	﹤0.01%	2611
2021 Q2	$44.2M	Sell	335,761 -124,526	-27%	-$16.6M	﹤0.01%	2783
2021 Q1	$59.3M	Sell	460,287 -2,376	-0.5%	-$361K	﹤0.01%	2514
2020 Q4	$77.2M	Buy	462,663 +7,400	+2%	+$1.22M	﹤0.01%	2229
2020 Q3	$70.3M	Sell	455,263 -28,454	-6%	-$4.09M	﹤0.01%	2096
2020 Q2	$71.5M	Buy	483,717 +82,938	+21%	+$11.4M	﹤0.01%	2053
2020 Q1	$45.1M	Sell	400,779 -22,769	-5%	-$2.96M	﹤0.01%	2113
2019 Q4	$58.9M	Sell	423,548 -30,429	-7%	-$3.38M	﹤0.01%	2257
2019 Q3	$43.7M	Sell	453,977 -255	-0.1%	-$28.4K	﹤0.01%	2380
2019 Q2	$52.3M	Buy	454,232 +30,827	+7%	+$3.69M	﹤0.01%	2295
2019 Q1	$49.8M	Sell	423,405 -22,906	-5%	-$2.01M	﹤0.01%	2282
2018 Q4	$28M	Sell	446,311 -14,650	-3%	-$921K	﹤0.01%	2552
2018 Q3	$32.7M	Buy	460,961 +22,172	+5%	+$1.53M	﹤0.01%	2606
2018 Q2	$29.2M	Buy	438,789 +32,980	+8%	+$2.17M	﹤0.01%	2650
2018 Q1	$26.5M	Sell	405,809 -25,533	-6%	-$1.44M	﹤0.01%	2610
2017 Q4	$17.3M	Buy	+431,342	New	+$15.7M	﹤0.01%	2856

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

BlackRock's ASND Position: Q2 2026 in Review

BlackRock increased its Ascendis Pharma A/S (ASND) stake by 235% in Q2 2026, buying an estimated $362M and bringing the position to 2,211,833 shares worth $590M. The position accounts for 0.01% of the portfolio, ranked #1100.

BlackRock first reported a position in ASND in Q4 2017 and has held it in 35 quarters since. 311 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

BlackRock held 2,211,833 shares of Ascendis Pharma A/S worth $590M as of Q2 2026.
BlackRock bought 1,550,779 Ascendis Pharma A/S shares in Q2 2026, an estimated $362M.
Ascendis Pharma A/S made up 0.01% of BlackRock's portfolio in Q2 2026, its #1100 holding.
BlackRock first reported a position in Ascendis Pharma A/S in Q4 2017 and has held it in 35 quarters since.
311 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.